PATIENT INFORMATION LEAFLET: INFORMATION FOR THE USER
Ebixa 10 mg film-coated tablets
Memantine hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Ebixa contains the active substance memantine hydrochloride. It belongs to a group of medicines called anti-dementia medicines.
Memory loss in Alzheimer's disease is due to a disturbance of signal transmission in the brain. The brain contains so-called N-methyl-D-aspartate (NMDA) receptors that are involved in the transmission of nerve signals that are important for learning and memory. Ebixa belongs to a group of medicines called NMDA receptor antagonists. Ebixa acts on these receptors, improving the transmission of nerve signals and memory.
Ebixa is used in the treatment of patients with moderate to severe Alzheimer's disease.
Do not take Ebixa
Warnings and precautions
Tell your doctor or pharmacist before you start taking Ebixa:
In these situations, treatment should be carefully supervised and your doctor should regularly re-evaluate the clinical benefit of Ebixa for you.
If you have kidney problems, your doctor should closely monitor your kidney function and, if necessary, adjust the dose of memantine.
If you have renal tubular acidosis (a condition where the blood becomes too acidic due to kidney problems) or severe urinary tract infections (infections of the urinary system), your doctor may need to adjust the dose of the medicine.
The use of memantine with other medicines such as amantadine (for the treatment of Parkinson's disease), ketamine (a medicine usually used as an anesthetic), dextromethorphan (a medicine for the treatment of cough) and other NMDA antagonists should be avoided.
Children and adolescents
Ebixa is not recommended for use in children and adolescents under 18 years of age.
Taking Ebixa with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
In particular, the administration of Ebixa may affect the action of the following medicines, so your doctor may need to adjust the dose:
If you are admitted to hospital, tell your doctor that you are taking Ebixa.
Taking Ebixa with food and drinks
You should tell your doctor if you have recently changed or intend to change your diet substantially (e.g. from a normal diet to a strict vegetarian diet), as your doctor may need to adjust the dose of the medicine.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy:Memantine is not recommended during pregnancy.
Breast-feeding:Women taking Ebixa should not breast-feed.
Driving and using machines
Your doctor will tell you whether your illness allows you to drive or use machines safely.
Also, Ebixa may affect your ability to react, so driving or operating machinery may be inappropriate.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose of Ebixa for adults and elderly patients is 20 mg once a day. To reduce the risk of side effects, this dose is achieved gradually by following the following daily scheme:
Week 1 | half a 10 mg tablet |
Week 2 | one 10 mg tablet |
Week 3 | one and a half 10 mg tablets |
Week 4 and subsequent weeks | two 10 mg tablets once a day |
The usual starting dose is half a tablet once a day (1 x 5 mg) for the first week. It is increased to one tablet a day (1 x 10 mg) for the second week and to one and a half tablets once a day for the third week. From the fourth week onwards, the usual dose is two tablets administered once a day (1 x 20 mg).
Dosage for patients with renal impairment
If you have kidney problems, your doctor will decide on the appropriate dose for your condition. In this case, your doctor should regularly check your kidney function.
Administration
Ebixa should be taken orally once a day. To get the most out of your medication, you should take it every day and at the same time. The tablets should be swallowed with a little water. The tablets can be taken with or without food.
Duration of treatment
Continue taking Ebixa as long as it is beneficial for you. Your doctor should regularly assess the effects of your treatment.
If you take more Ebixa than you should
If you forget to take Ebixa
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Generally, side effects are mild to moderate.
Common (affects 1 to 10 users in 100):
Uncommon (affects 1 to 10 users in 1,000):
Rare (affects 1 to 10 users in 10,000):
Frequency not known (frequency cannot be estimated from the available data):
Alzheimer's disease has been associated with depression, suicidal ideation and suicide. These events have been reported in patients treated with Ebixa.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Annex V.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
What Ebixa contains
The active substance is memantine hydrochloride. Each film-coated tablet contains 10 mg of memantine hydrochloride, equivalent to 8.31 mg of memantine.
The other ingredients are microcrystalline cellulose, sodium croscarmellose, anhydrous colloidal silica and magnesium stearate, in the tablet core, and hypromellose, titanium dioxide (E 171), macrogol 400 and yellow iron oxide (E 172), in the tablet coating.
Appearance and packaging
Ebixa is presented as film-coated tablets, pale yellow to yellow in color, oval in shape, with a break line and engraved "1 0" on one side and "M M" on the other side. The tablet can be divided into equal doses.
Ebixa tablets are presented in packs of 14, 28, 30, 42, 49 x 1, 50, 56, 56 x 1, 70, 84, 98, 98 x 1, 100, 100 x 1, 112, 980 (10 x 98) or 1000 (20 x 50) film-coated tablets. The packs of 49 x 1, 56 x 1, 98 x 1 and 100 x 1 film-coated tablets are presented in single-dose blisters.
Not all pack sizes may be marketed.
Marketing authorisation holder and manufacturer
Ottiliavej, 9
2500 Valby
Denmark
For further information about this medicine, contact the local representative of the marketing authorisation holder.
Belgium/België/Belgien Lundbeck S.A./N.V. Tel: +32 2 535 7979 | Lithuania
Tel: +45 36301311 |
Bulgaria Lundbeck Export A/S Representative Office Tel: +359 2 962 4696 | Luxembourg/Luxemburg Lundbeck S.A. Tel: +32 2 340 2828 |
Czech Republic Lundbeck Ceská republika s.r.o. Tel: +420 225 275 600 | Hungary Lundbeck Hungaria Kft. Tel: +36 1 4369980 |
Denmark Lundbeck Pharma A/S Tel: +45 4371 4270 | Malta
Tel: +45 36301311 |
Germany Lundbeck GmbH Tel: +49 40 23649 0 | Netherlands Lundbeck B.V. Tel: +31 20 697 1901 |
Estonia
Tel: +45 36301311 | Norway
Tel: +47 91 300 800 |
Greece Lundbeck Hellas S.A. Tel: +30 210 610 5036 | Austria Lundbeck Austria GmbH Tel: +43 1 266 9108 |
Spain Lundbeck España S.A. Tel: +34 93 494 9620 | Poland Lundbeck Poland Sp. z o. o. Tel: +48 22 626 93 00 |
France Lundbeck SAS Tel: +33 1 79 41 29 00 | Portugal Lundbeck Portugal Lda Tel: +351 21 00 45 900 |
Croatia Lundbeck Croatia d.o.o. Tel: +385 1 6448263 | Romania Lundbeck Export A/S Tel: +40 21319 88 26 |
Ireland Lundbeck (Ireland) Limited Tel: +353 1 468 9800 | Slovenia Lundbeck Pharma d.o.o. Tel: +386 2 229 4500 |
Iceland Vistor hf. Tel: +354 414 7070 | Slovakia Lundbeck Slovensko s.r.o. Tel: +421 2 5341 42 18 |
Italy Lundbeck Italia S.p.A. Tel: +39 02 677 4171 | Finland Oy H. Lundbeck Ab Tel: +358 2 276 5000 |
Cyprus Lundbeck Hellas A.E Tel: +357 22490305 | Sweden
Tel: +46 4069 98200 |
Latvia
Tel: +45 36301311 | United Kingdom Lundbeck Limited Tel: +44 1908 64 9966 |
Date of last revision of this leaflet:MM/YYYY
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.